Scarica l'app Stockscreener
34.94
17.05%
5.09
Pre-mercato:
37.50
2.56
+7.33%
Precedente Chiudi:
$29.85
Aprire:
$30.23
Volume 24 ore:
622.75K
Relative Volume:
0.97
Capitalizzazione di mercato:
$113.74M
Reddito:
$27.47M
Utile/perdita netta:
$-26.60M
Rapporto P/E:
-7.57
EPS:
-4.6156
Flusso di cassa netto:
$-21.86M
1 W Prestazione:
+180.53%
1M Prestazione:
+547.40%
6M Prestazione:
+58.83%
1 anno Prestazione:
+49.66%
Intervallo 1D:
$29.50
$35.50
Intervallo di 1 settimana:
$12.00
$38.00
Portata 52W:
$4.971
$38.00
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
34.94 | 113.74M | 27.47M | -26.60M | -21.86M | -4.6156 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Cue Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Cue Biopharma (CUE) Stock Surges Following Financing Deal and Le - GuruFocus
Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise - TechStock²
Cue Biopharma jumps as investors react to Ascendant-221 licensing deal and fresh financing news - Quiver Quantitative
Cue Biopharma licenses Ascendant-221 and raises new capital - TipRanks
Cue Biopharma Raises $30 Million in Private Placement to Advance Immunology Pipeline - citybiz
MSN Money - MSN
Cue resets strategy with new CEO, pipeline deal and $30m financing - The Pharma Letter
Cue Biopharma raises $30M in private placement - MSN
Cue Biopharma appoints Shao-Lee Lin as CEO and president - Investing.com UK
CUE Stock Quote Price and Forecast - CNN
CUE Stock Price, Quote & Chart | CUE BIOPHARMA INC (NASDAQ:CUE) - ChartMill
Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving? - Benzinga
$Cue Biopharma (CUE.US)$ - Moomoo
Cue Biopharma secures $30M private placement financing - Investing.com UK
Cue Biopharma Secures $30 Million Financing and New CEO - Intellectia AI
Cue Biopharma (CUE) Secures $30M in Private Placement Financing - GuruFocus
Cue Biopharma Names Lin as CEO, Secures Exclusive License Agreement With Ascendant Health Sciences - Moomoo
Cue Biopharma unveils leadership changes, pipeline milestones and financing to drive phase 2 strategy - Traders Union
Cue Biopharma secures $30M private placement financing By Investing.com - Investing.com Australia
Cue Biopharma Announces $30 Million Private P - Moomoo
Cue Biopharma licenses anti-IgE antibody for allergic diseases By Investing.com - Investing.com South Africa
Cue Biopharma appoints Shao-Lee Lin as CEO and president By Investing.com - Investing.com Australia
Cue Biopharma lines up $30M to fund pipeline and Ascendant-221 - Stock Titan
Cue Biopharma licenses anti-IgE antibody for allergic diseases - Investing.com
Cue pays $15M for allergy drug, targets food allergy trial - Stock Titan
Cue Biopharma Announces $30 Million PIPE Financing Agreement to Advance Clinical Pipeline - Quiver Quantitative
Press Release: Cue Biopharma Announces $30 Million Private Placement - Moomoo
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody - The Manila Times
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company - The Manila Times
CUE - Finviz
Cue Biopharma, Inc. Revenue Breakdown – SWB:1UC0 - TradingView
Current ratio of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Taxes of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — SWB:1UC0 - TradingView
Cue Biopharma (Nasdaq: CUE) adds Ascendant-221 and raises $30M - Stock Titan
Cue Biopharma (CUE) price target increased by 2,900.00% to 122.40 - MSN
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma (FRA:1UC0) Unearned Income - GuruFocus
Cue Biopharma, Inc. Income Statement – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Cash Flow – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — GETTEX:1UC0 - TradingView
Equity in earnings of Cue Biopharma, Inc. – LSX:A426PN - TradingView
Cue Biopharma, Inc. Cash Flow – LSX:A426PN - TradingView
Equity in earnings of Cue Biopharma, Inc. – GETTEX:1UC0 - TradingView
Net debt of Cue Biopharma, Inc. – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — LSX:A426PN - TradingView
Cue Biopharma, Inc. Balance Sheet – LSX:A426PN - TradingView
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):